Immune checkpoint blockade (ICB) exemplifies this approach by employing antibodies to target inhibitory receptors such as PD-1 and CTLA-4 on T cells and PD-L1 on tumors, thereby preventing tumor-driven suppression of T cell activity. This evidence concerns the gene CTLA4 and neoplasm.